Novo Nordisk ® es care sales growth is driven by GLP-1 patients and value market share in IO Number of patients (millions) Class growth ~50% Value market share 6 75% 65.2% 5 60% 4 43.7% 45% 3 32.3% 30% 2 1 1 8 2 . . 7 8 % % 15% 0 Feb-21 Feb-22 0% Feb-23 GLP-1 patients Rybelsus ® Ozempic ® dulaglutide wan; RoW: Rest of World; CER: Constant exchange rates c’ 22- Feb’23 vs Dec’21 - Feb’22 (Rolling 3 month average) ge daily doses Victoza ® NN GLP-1
Download PDF file